As part of a broader wave of 2026 cost-saving moves, the layoff tracker reports that enGene Therapeutics is halving its workforce while preparing an eventual BLA submission for its sole clinical program, detalimogene voraplasmid. enGene said it will reduce staff by about 50%, with three C-suite exits planned, and aims to start BLA activities in the second half of the year. The report situates enGene’s decision alongside Neumora’s restructuring following its late-stage depression setbacks and notes Genentech’s earlier internal research leadership changes. For industry teams, the comparison highlights two distinct dynamics: workforce reductions tied to cash preservation for clinical catalysts, and rapid labor reallocation after clinical efficacy failures. For operators, these signals matter for planning—talent pipelines, trial execution bandwidth, and the ability to maintain parallel programs while corporate bandwidth tightens.